Patient characteristics are summarised in Table 1. Patients were on average 56.3 years of age, predominantly white ethnicity and female. A quarter were in full or part time employment. Nearly two-thirds had a co-morbid condition. Musculoskeletal pain patients were the largest patient group (31%). SMP completion rates (≥5 SMP sessions) averaged 69% (805/1170)1 across all 4 LTCs. Where we could establish

direct pairing of data from patients who completed baseline and 6 month surveys and who attended ≥5 SMP sessions for the main analysis, there were 486 matched PAM scores. Response rates were lower for other outcome measures as we only collected PAM data at 6 months follow-up among those patients who were subject to repeat follow-up attempts. Patients who completed the SMP tended to be significantly older (mean age 59 years compared to 55 years), significantly

less anxious (mean 10.0 compared to 10.9) and significantly Pirfenidone less depressed (mean 8.0 compared to 8.6) than those who dropped MAPK inhibitor out of the SMP (attended 0–4 sessions). These findings are confounded with the lower completion rates among patients with depression (63% compared to CCH average of 69%), who also tended to be younger and more anxious than patients with other LTC diagnoses. There were no other demographic differences, between patients who completed the SMP and those patients who did not complete the SMP on variables of gender, ethnicity, house ownership, living arrangements, education, employment, co-morbidity, patient activation, health status or quality of life (Table 2). Patient activation significantly improved 6 months after completing the SMP (p < 0.001, effect size = 0.65) ( Table 3). None of the prognostic and demographic factors predicted patient activation over time. ITT analysis produced similar results. 53.9% of patients showed a Selleck Cisplatin meaningful improvement (i.e. ≥4 points) in patient activation scores. Patients’ health status as measured by EQ-VAS significantly improved 6 months after completing the SMP (p < 0.001,

ES = 0.33) ( Table 2). None of the prognostic and demographic factors predicted health status over time. Intention to Treat (ITT) analysis produced similar results. Patients’ health-related quality of life significantly improved 6 months after completing the SMP (p = 0.042, ES = 0.06) ( Table 2). Condition was a predictor of change in quality of life over time (p < 0.045). Health-related quality of life was lower at baseline for depression and patients with musculoskeletal pain in comparison to that of patients with COPD and patients with diabetes. Furthermore, improvements at 6 months follow-up were greater in these patients. ITT analysis produced similar results. Patients’ anxiety and depression decreased significantly 6 months after completing the SMP (both p < 0.001, ES = 0.37 and 0.31 respectively) ( Table 2). Condition was apredictor of change in anxiety over time (p < 0.001).